Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 8
---
 the Securities Act, and Section 21E of the Securities Exchange Act. All
statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of
operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical
studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success,
as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements.

In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“believe,” “estimate,” “predict,” “potential,” or “continue” or the negative
of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to,
statements about:

| ● | our financial performance; |

| ● | our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements, including the development and, if approved, commercialization of our product candidates; |

| ● | our ability to realize the benefits expected from the Business Combination pursuant to the Business Combination Agreement; |

| ● | the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; |

| ● | the scope, progress, results and costs of developing CER-1236 or any other product candidates we may develop, and conducting preclinical studies and clinical trials; |

| ● | the timing and costs involved in obtaining and maintaining regulatory approval of CER-1236 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations or accelerated approvals for our drug candidates for various indications; |

| ● | current and future agreements with third parties in connection with the development and commercialization of CER-1236 or any other future product candidate; |

| ● | our ability to advance product candidates into and successfully complete clinical trials; |

| ●